⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694838 | 1.00 | — | — | |
| SCHEMBL2675782 | 1.00 | — | — | |
| SCHEMBL7804 | 1.00 | — | — | |
| SCHEMBL8015149 | 1.00 | — | — | |
| SCHEMBL1890701 | 1.00 | — | — | |
| SCHEMBL8661925 | 1.00 | — | — | |
| SCHEMBL131783 | 1.00 | — | — | |
| SCHEMBL21774 | 1.00 | — | — | |
| SCHEMBL8420181 | 1.00 | — | — | |
| SCHEMBL11234658 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4221907-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1980-09-09 | — | — | US | claimed |
| WO-2024076934-A2 | COMPOSITIONS AND METHODS FOR MODULATION OF CFTR | CYSTIC FIBROSIS FOUNDATION (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024026122-A2 | COMPOUNDS FOR TREATMENT OF CONDITIONS AND DISEASES | STOKE THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240033358-A1 | COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS | NOVARTIS AG (CH) | 2024-02-01 | — | — | US | disclosed |
| US-20230116704-A1 | ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | STOKE THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-115087452-A | Antisense oligomers for the treatment of conditions and diseases | 斯托克制药公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021113541-A1 | ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | STOKE THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20150056186-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | HOFFMANN-LA ROCHE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140004104-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | HOFFMANN-LA ROCHE INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2604277-A1 | Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent | Roche Glycart AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | Hoffman-La Roche. Inc. (US) | 2011-04-14 | — | — | US | disclosed |
| EP-2203185-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Roche Glycart AG (CH) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009049841-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | ROCHE GLYCART AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-4232150-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4221907-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1980-09-09 | — | — | US | disclosed |